|
|
|
|
|
|
|
|
|
|
"This is a great day for all of our stakeholders as well as women who will benefit from OVA1,' said Gail Page, executive chair of Vermillion. 'We are in a position to resume development of our other programs in ovarian cancer and peripheral arterial disease,' she added."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.